Granules India Limited

Granules India Limited

Granules India Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026 regarding the utilization of proceeds from its preferential issue of equity shares completed in February 2026. The report, issued by India Ratings & Research, confirms no deviation from the stated objects of the issue, based on management undertakings and a statutory auditor certificate. The filing is made pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. No adverse findings were noted, and the report is being submitted to NSE and BSE for record.

Granules India Limited

Granules India Limited notified the National Stock Exchange that it will share a presentation related to an analysts/institutional investor meet or conference call. The announcement does not disclose any specific financial results, strategic initiatives, or other material information. It is a routine procedural update regarding investor communication.

Granules India Limited

Granules India Limited announced its unaudited financial results for Q1 FY27, reporting revenue from operations of INR 14,768 million, a 22% year‑on‑year increase. EBITDA rose to INR 3,389 million (+37% YoY) and profit after tax reached INR 1,800 million (+60% YoY). Net debt declined sharply to INR 1,012 million, reducing the net debt‑to‑EBITDA ratio to 0.07x, while ROCE improved to 18.0%. The company highlighted strong performance across its API, finished dosage, PFI and peptides CDMO segments and reiterated focus on regulatory excellence and portfolio transformation.

Granules India Limited